CDC advisers reconvene to weigh next steps on Johnson & Johnson vaccine after rare, serious blood clots

A federal vaccine advisory committee is reconvening Friday to discuss next steps for Johnson & Johnson’s coronavirus vaccine after health officials recommended last week that states pause use while six U.S. cases of a rare and severe type of blood clot were reviewed.

That independent expert panel, the Advisory Committee on Immunization Practices, last met April 14. It reviewed the decision made the day before by the Centers for Disease Control and Prevention and the Food and Drug Administration to recommend a temporary halt in giving the vaccine following reports...